BioCryst Pharmaceuticals,Inc. (BCRX)

[Buy-Ford-Now]

BioCryst Pharm target raised to $6.50 at MLV & Co

BioCryst Pharm target raised to $6.50 at MLV & Co (4.29 -0.21)
MLV & Co raises their BCRX tgt to $6.50 from $3. Following this week's announcement of positive results from a Phase I trial of BCX4161 for the prevention of hereditary angioedema (HAE) attacks, they added the compound to their BCRX estimates and valuation. While they acknowledge that the 120% gain over the last 4 trading sessions may serve to constrain further near-term appreciation, they remain positive on the shares, especially in light of an NDA filing for peramivir expected by year-end;
BUY
Seeking Alpha article
 http://seekingalpha.com/article/1599712-biocryst-the-next-orphan-drug-1b-company?source=yahoo
 
 ". . . we think that an oral prophylactic therapy like BCX4161 could be a $1B+ product.

FYI, $BCRX Goldman is going 5-10 cents above the Ask to purchase blocks of stock ???????